Cáncer de pulmón no microcítico

  1. Expósito, F. Navarro
  2. González, J.L. López
  3. Castillo, C.
  4. Losada, C.
  5. Soto, M. Álvarez-Mon
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Título del ejemplar: Enfermedades oncológicas (I) Cáncer de pulmón. Cáncer de cabeza y cuello

Serie: 12

Número: 31

Páginas: 1811-1824

Tipo: Artículo

DOI: 10.1016/J.MED.2017.04.001 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Resumen Introducción El cáncer de pulmón se ha convertido en un importante problema de salud pública debido a su elevada incidencia y mortalidad. Es la principal causa de mortalidad relacionada con el cáncer en todo el mundo. Etiopatogenia Existe un amplio número de factores ambientales asociados al desarrollo de cáncer de pulmón, de todos ellos el hábito tabáquico es el más importante. Histología El 85% de los cánceres de pulmón diagnosticados corresponden a carcinomas de células no pequeñas y, dentro de estos, el tipo histológico más frecuente es el adenocarcinoma, con un aumento de su incidencia en los últimos años. Tratamiento En el momento del diagnóstico, más del 50% se presentan con enfermedad localmente avanzada o metastásica, con una supervivencia del 15% a 5 años. El cáncer de pulmón no microcítico (CPNM) constituye un grupo de entidades que difieren en cuanto al curso clínico y pronóstico y, por tanto, con diferentes posibilidades terapéuticas, basadas en la combinación de la cirugía, quimioterapia y radioterapia. En los últimos años, la identificación de dianas moleculares oncogénicas ha permitido el desarrollo de tratamientos personalizados.

Referencias bibliográficas

  • Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF. SEER Cancer Statistics Review, 1975-2013, National Can-cer Institute. Bethesda, MD, based on November 2015 SEER data submission.
  • Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123:21S.
  • Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
  • Corrin B, Nicholson AG, editors. Pathology of the lungs. Philadelphia: Churchill Livingstone Elsevier; 2006.
  • López-Ríos F, de Castro J, Concha A, Garrido P, Gómez-Román J, Isla D. Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica. Revista Española de Patología. 2015;48(2):80-9.
  • Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest. 1974;65:299.
  • Thomas L, Kwok Y, Edelman MJ. Management of paraneoplastic syn-dromes in lung cancer. Curr Treat Options Oncol 2004; 5:51.
  • Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines. 2ª ed. Chest. 2007;132:S149.
  • Munden, RF, Swisher, SS, Stevens, CW, Stewart, DJ. Imaging of the patient with nonsmall cell lung cancer. Radiology. 2005; 237:803.
  • Verschakelen JA, De Wever W, Bogaert J. Role of computed tomography in lung cancer staging. Curr Opin Pulm Med. 2004;10:248.
  • Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, et al. WK18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007;99(23):1753-67.
  • Ernst A, Silvestri GA, Johnstone D. Interventional pulmonary proce-dures: Guidelines from the American College of Chest Physicians. Chest. 2003;123:1693.
  • Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706.
  • Ferguson MK, Lehman AG. Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg. 2003;76:1782.
  • Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60:615.
  • Petersen RP, Pham D, Burfeind WR, Hanish SI, Toloza EM, Harpole DH Jr. Thoracoscopic lobectomy facilitates the delivery of chemo-therapy after resection for lung cancer. Ann Thorac Surg. 2007;83:1245.
  • Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax. 2001;56:628.
  • Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998; 352:257.
  • Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899.
  • Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol. 2006;1:611.
  • Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage i (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247-53
  • Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. 2007;(3):CD006157.
  • Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) nonsmall cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) (abstract). J Clin Oncol. 2005;23:624s.
  • Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13): 2181-90.
  • Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007;25:1698-704.
  • Bezjak A, Temin S, Franklin G, Giaccone G, Govindan R, John-son ML. Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence Based Clinical Practice Guideline. J Clin Oncol. 2015;33(18):2100-5.
  • Ohe Y, Ohashi Y, Kubota K, Nakagawa K, Negoro S, Nishiwaki Y. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317-23.
  • Azzoli CG, Kris MG, Pfister DG. Cisplatin versus carboplatin for pa-tients with metastatic non-small-cell lung cancer--an old rivalry renewed. J Natl Cancer Inst. 2007;99:828.
  • Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small cell lung cancer: a systematic re-view and meta-analysis of randomized trials. J Clin Oncol. 2009;27(20):3277
  • Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543.
  • Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin gemcitabine in advanced non-small cell lung cancer. Ann Oncol. 2010;21(3):556.
  • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A. Paclitaxel carboplatin alone or with bevacizumab for non-small-cell lung cancer. Engl J Med. 2006;355(24):2542.
  • Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy naive patients with advanced or recurrent non-squamous non small cell lung cancer (abstract). J Clin Oncol. 2007;25:967s.
  • Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first line therapy for nonsquamous non-small cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227.
  • Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N. Safety and efficacy of first line bevacizumab-based therapy in advanced non squamous non-small cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):733.
  • Vélez M, Arango BA, Pérez CA, Santos ES. Safety and efficacy of pemetrexed in maintenance therapy of non-small cell lung cancer. Clin Med Insights Oncol. 2012;6:117-24.
  • Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13(3):247-55.
  • Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M. Prospective randomized trial of Docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum based chemotherapy. J Clin Oncol. 2000;18:2095-103.
  • Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-97.
  • Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (Lume-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2):143-55.
  • Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second line treatment of stage IV non small cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-73.
  • Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non small cell lung cancer. N Engl J Med. 2015;373:123-35.
  • Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627-39.
  • Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non small cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-50.
  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947.
  • Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR mutation positive non small cell lung cancer after progression on first line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990-8.
  • Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C. Erlotinib versus chemotherapy as first line treatment for patients with advanced EGFR mutation-positive non small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735.
  • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutation-positive non small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239.
  • Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-34.
  • Haaland B, Tan PS, de Castro G Jr, Lopes G. Meta-analysis of first line therapies in advanced non small cell lung cancer harbor-ing EGFR activating mutations. J Thorac Oncol. 2014;9(6):805-11.
  • Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N. Afatinib versus cisplatin based chemotherapy for EGFR mutation positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141-51.
  • Aix SP, Park K, Tan EH, O’Byrne K, Zhang L, Boyer M. P1.34: first line afatinib vs gefitinib for patients with EGFR mutation positive non small cell lung cancer: The LUX-Lung 7 Trial: track: advanced NS-CLC. J Thorac Oncol. 2016;11(10S):S203-S204.
  • Tan CS, Cho BC, Soo RA. Next generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor mutant non small cell lung cancer. Lung Cancer. 2016;93:59-68.
  • Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non small cell lung cancer (FLEX): an open label randomised phase III trial. Lancet. 2009;373(9674):1525.
  • Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T. First line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167-77.
  • Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ. Crizotinib versus chemotherapy in advanced AL positive lung cancer. N Engl J Med. 2013;368:2385-94.
  • Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ. Ceritinib in ALK rearranged non small cell lung cancer. N Engl J Med. 2014;370:1189-97.
  • Srinivasamaharaj S, Salame BK, Rios-Perez J, Kloecker G, Perez CA. The role of alectinib in the treatment of advanced ALK-rearranged non small cell lung cancer. Expert Rev Anticancer Ther. 2016:16(12):1-7.
Fuente de los datos: Dialnet